The FDA has warned patients and clinicians about compounded ketamine products, including oral forms, used for psychiatric conditions. Its main points are that compounded products are not FDA-approved, that ketamine is not approved for any psychiatric disorder, and that using these products without a clinician monitoring you may put you at risk for serious adverse events.
Part of our guide: A Patient’s Guide to Ketamine and Spravato
So is at-home ketamine safe? There is no solid answer for all products and all people, because the safety research is limited. What is clear is that home use removes the onsite monitoring that the FDA treats as an important safeguard. It is a decision to make with full information and a clinician who knows your health.
If you are thinking about suicide or are in danger, call or text 988 (988 Suicide & Crisis Lifeline), call 911 or go to the nearest ER.
The FDA actions, in order
- February 16, 2022. The FDA issued a risk alert to health care professionals about compounded ketamine nasal spray.
- October 10, 2023. The FDA warned patients and health care providers about potential risks of compounded ketamine products, including oral formulations, for psychiatric disorders.
- June 27, 2024. The agency held a public workshop through the Reagan-Udall Foundation on current ketamine use, covering safety concerns and online access.
- June 23, 2026. The date on FDA warning letters to online sellers offering ketamine liquid, troches (lozenges) and nasal spray. The FDA pages show a content date of July 7, 2026.
What the FDA alerts said
The FDA's October 2023 alert makes these main points:
- Ketamine is not FDA-approved for any psychiatric disorder, and the FDA has not determined it is safe and effective for those uses.
- Compounded products are not FDA-approved. That means the FDA has not evaluated their safety, effectiveness or quality before marketing, and they have no approved uses or routes.
- Using them without monitoring by a clinician for sedation, dissociation and vital-sign changes, such as blood pressure and heart rate, may put patients at risk for serious adverse events.
- Known concerns with ketamine products include abuse and misuse, psychiatric events, higher blood pressure, slowed breathing, and lower urinary tract and bladder symptoms.
- The FDA is not aware of evidence that compounded ketamine is safer, more effective or faster-acting than FDA-approved psychiatric medicines.
- Because compounded products have no REMS monitoring requirement, they may be less safe.
- Safe or effective dosing has not been established for any psychiatric use, and doses of compounded oral and sublingual products may vary.
- In April 2023 the FDA received a report of slowed breathing in a patient who took compounded oral ketamine outside a health care setting. The blood level appeared to be twice the level typically obtained for anesthesia.
What the FDA did not say
A March 2025 meeting summary from the Reagan-Udall Foundation for the FDA says these alerts were not meant to prohibit compounding, and were meant to inform the public about risks. The 2023 alert itself notes that compounded medicines can serve an important need for certain patients when an approved drug is not medically appropriate, and that they should be used only under a clinician's care.
It is also worth separating two things. FDA-approved ketamine is an injectable anesthetic, and the agency says its expected benefit outweighs these risks when used at appropriate doses for approved uses and routes. That statement does not extend to at-home use for depression.
What the 2026 warning letters added
The June 2026 letter to an online seller is blunt. The FDA wrote that it has identified significant risks associated with unapproved ketamine products, especially without appropriate medical supervision, and that easy availability online puts consumers at risk for serious adverse events. It added that products outside regulatory safeguards may be contaminated, counterfeit, contain varying amounts of active ingredients, or contain different ingredients altogether.
That letter concerned a website selling without a prescription, which the FDA said jeopardizes patient safety. It is a different situation from a licensed prescriber and a pharmacy, though the home-use questions below still apply. In the same letter, the FDA noted that prescription drugs can be used safely only at the direction and under the supervision of a licensed practitioner.
Why monitoring matters
Spravato shows how the FDA handles the related drug esketamine. Its label carries boxed warnings for:
- Sedation, dissociation and respiratory depression. Patients can become sleepy, feel disconnected, or have slowed or stopped breathing after a dose, so they must be monitored for at least 2 hours at each session and then assessed before they can leave.
- Abuse and misuse. Spravato is a Schedule III controlled substance. Risk should be weighed before prescribing and watched for during treatment.
- Suicidal thoughts and behaviors in young people. Antidepressants increased these risks in pediatric and young adult patients in short-term studies. All antidepressant-treated patients should be watched closely for worsening or new suicidal thoughts. Spravato is not approved for anyone under 18.
Under the REMS safety program, certified settings must have a prescriber onsite, have staff and a pulse oximeter to monitor patients, and must not dispense Spravato for use elsewhere. Spravato is never taken at home.
The Reagan-Udall summary lists problems that can arise when ketamine is used alone, adapted from a workshop presentation:
- panic or anxiety with no one present to help
- driving after a dose, or being responsible for children while not fully alert
- a child accidentally swallowing the medicine
- keeping extra doses, and using large doses
- selling extra doses to others
- developing a ketamine use disorder
What the data show so far
The picture is still incomplete. The Reagan-Udall summary says the impact of prescribing ketamine solely through telehealth, with multiple doses mailed home, has yet to be understood. Other data come with caveats:
- Advertising is common. In a 2025 review of 233 clinics advertising in the New York metropolitan area, 36.5% prescribed ketamine for at-home use and 42.9% advertised oral ketamine.
- Poison center reports rose. US poison centers recorded 205 ketamine exposures in 2019 and 414 in 2023. These reports include misuse and suspected suicide attempts and do not show how many came from prescribed home treatment.
- Ads are not always accurate. A Maryland study of 17 advertisers found that seven did not disclose any potential adverse effects, and ten did not disclose off-label use.
- One study tablet was reported as well tolerated. A phase 2 trial of an investigational extended-release tablet reported most dosing at home during the randomized phase, with good tolerability. That product is a specific study tablet, tested in people who had responded early, so it cannot be assumed to apply to compounded lozenges or liquids.
Warning signs and questions to ask
Be cautious if a seller or website:
- does not require a prescription or a real medical evaluation
- says ketamine is FDA-approved for depression or nonaddictive
- does not mention off-label use or side effects
- offers no clear plan for emergencies
Whatever the setting, it is reasonable to ask:
- Is this product FDA-approved or compounded, and from which pharmacy?
- Who checks blood pressure, sedation and breathing, and when?
- Must another adult be present, and what are they told to do?
- How are doses stored and limited, especially with children at home?
- Who answers the phone, at any hour, if something goes wrong?
- What is the plan for a change in mood or thoughts of suicide?
If you already use ketamine at home
Do not stop or change it on your own. Talk with your prescriber, and tell any other clinician you see. If you have a side effect, you can report it to the FDA at 1-800-FDA-1088 or fda.gov/medwatch. If you have trouble breathing, cannot stay awake or feel unsafe, call 911.
Where to learn more
For background on safety, read this article on ketamine risks and benefits and this comparison of routes. For how Mind Body Seven approaches this treatment, see its ketamine therapy page or its Spravato page.
FAQs
Is a telehealth ketamine prescription illegal?
This article does not address the law on telehealth prescribing of controlled substances. Rules change and vary, and this is not legal advice. Ask the prescriber how they meet current federal and state requirements.
Is Spravato ever available to use at home?
No. Under the REMS it is taken under direct observation in a certified healthcare setting, and it may not be dispensed for use elsewhere.
Does having someone nearby make home use safe?
A person nearby may help in an emergency, but that does not replace clinical monitoring, and they may not know what to look for. Ask your prescriber what role they should play.
